Product Description
Zidovudine (azidothymidine) is a thymidine analogue antiretroviral drug active against human immunodeficiency virus (HIV). In acquired immunodeficiency syndrome (AIDS) and AIDS-related complex (ARC) patients, orally and intravenously administered zidovudine is effective in reducing the incidence of opportunistic infections and neoplasms, increasing helper T lymphocyte numbers, and improving survival rates and quality of life. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/2661194/)
Mechanisms of Action: NRT Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: GSK
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: HIV Infections
Phase 2: Acquired Immunodeficiency Syndrome
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| ACTRN12621001354875 | P2 |
Active, not recruiting |
Acquired Immunodeficiency Syndrome|HIV Infections |
2022-09-27 |
2024-08-29 |
Patient Enrollment|Treatments|Trial Status |
|
| D3 | P3 |
Active, not recruiting |
HIV Infections |
2026-04-03 |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
03/12/2024 |
News Article |
ARIA Cybersecurity Wins Globee Cybersecurity Product Award for AZT PROTECT |
|
03/07/2024 |
News Article |
Aztec Reports Final Gold and Multi-Element Results From 2023 RC Drilling from the Cervantes Project, Sonora, Mexico; Multiple, Shallow and Broad, Oxidized Gold Intercepts Continue the Expansion of the California Target Mineralized Zone |
|
03/05/2024 |
News Article |
FPX Nickel Outlines Baptiste Nickel Project Advancement Activities |
|
03/01/2024 |
News Article |
FPX Nickel Appoints Market Maker |